Psoriatic arthritis is a chronic inflammatory arthritis associated with psoriasis, causing joint pain, stiffness, swelling, and possible progressive joint damage if untreated.
AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
Real-world and trial data show ixekizumab and deucravacitinib provide durable efficacy in psoriatic arthritis. Ixekizumab achieved high remission rates and drug retention over 24 months, while deucravacitinib improved outcomes across multiple disease domains in the phase III POETYK PsA-2 trial.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
MoonLake Immunotherapeutics plans to submit an FDA Biologics License Application for Sonelokimab in hidradenitis suppurativa by the end of September following a positive pre-BLA meeting. The submission is supported by clinical trial data showing 43% of patients achieved high-level improvement by Week 12 in the Mira trial. The company is also expecting multiple Phase 3 data readouts throughout the year.
Recent research highlights advances in precision medicine for psoriatic arthritis, including a biopsy-driven treatment strategy that improved clinical outcomes and ongoing investigation into new biologic agents, combinations, and biomarker panels.
Johnson & Johnson said Tremfya met the primary endpoint in the Phase 3 FUZION study in active perianal fistulizing Crohn’s disease. At Week 24, both Tremfya dosing regimens showed statistically significant combined fistula remission versus placebo.
Dr. Reddy's said the FDA accepted for review its 351(k) BLA for DRL_AB, a proposed interchangeable biosimilar to ORENCIA. The application covers an IV formulation for RA, PsA and pJIA.
Bio-Thera Solutions expands its partnership with Intas Pharmaceuticals for BAT2506, a golimumab biosimilar, through an exclusive commercialization agreement for India. The India biosimilars market is projected to grow from $184 million to $1.02 billion by 2035, driven by patent expirations and strategic partnerships.
AbbVie reported Q4 earnings that beat consensus estimates with $16.62 billion in revenue, while facing competitive setbacks in psoriatic arthritis and Medicare pricing challenges for Botox.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07772687 |
Prospective Analysis of Blood Flow Restriction Training in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Compared to Conventional Strength Training |
COMPLETED | NA |
| NCT07718815 |
HLA B Leader in Patients With Psoriatic Arthritis |
RECRUITING | NA |
| NCT07653009 |
Transcutaneous Auricular Vagus Nerve Stimulation in Psoriatic Arthritis |
RECRUITING | NA |
| NCT07594054 |
Inflammation Digital Biomarkers Validation Study |
NOT_YET_RECRUITING | |
| NCT07580092 |
Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With Inflammatory Joint Disease |
COMPLETED | |
| NCT07567378 |
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry |
NOT_YET_RECRUITING | |
| NCT07486960 |
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) |
RECRUITING | PHASE2 |
| NCT07406035 |
A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis |
RECRUITING | PHASE2 |
| NCT07403890 |
Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis |
NOT_YET_RECRUITING | NA |
| NCT07398651 |
Apremilast and Adalimumab in Psoriatic Arthritis Patients |
NOT_YET_RECRUITING | NA |
